3 Growth Shares For Your Nisa: AstraZeneca plc, Diageo plc And Unilever plc

AstraZeneca plc (LON:AZN), Diageo plc (LON:DGE) and Unilever plc (LON:ULVR) look to be three great growth picks for your new ISA.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

At the beginning of this month the much touted New ISA, or Nisa, came into existence.

The Nisa is a revolution for savers. The new product has a limit of £15,000, a substantial increase from the £11,880 allowed in the previous Stocks & Shares ISA. What’s more, you will be able to move freely between shares and cash at any time using the full £15,000 to invest in the stock market, cash or a mix of both.

For those investors who want to add some spice to their Nisa, here are three companies that are set to see their profits surge over the next few years.

Best of both worldsastrazeneca

Recent takeover candidate, AstraZeneca (LSE: AZN) (NYSE: AZN.US) is not only a company with great growth potential, the company’s shares also currently support a 4% dividend yield.

As part of its attempt to rebuff Pfizer, Astra made the claim that the company had the potential to nearly double its annual sales during the next 10 years — from $26 billion today to $45 billion by 2023.

If the company pulls it off, shareholders will be richly rewarded. There is no reason to suggest that the company cannot hit these lofty targets.

Indeed, it is believed that Astra’s current pipeline of oncology treatments is one of the best in the world. The company’s set of AZD9291 cancer treatments is expected to rack up sales of $3 billion, as its flexible nature means that the drug can be combined with other treatments to make several completely different products.

However, at present Astra’s sales are contracting, although current forecasts predict that they will start expanding again during 2016 and 2017. With a dividend yield of 4%, investors will be paid to wait.

Rapid expansion

DiageoDiageo’s (LSE: DGE) (NYSE: DEO.US) growth over the past decade has been nothing short of impressive. Nevertheless, it would appear that the company is just getting started.

Diageo has built itself into the largest alcoholic beverage brand in the world. The company’s drinks cabinet now contains some of the world’s best-known drinks brands including Guinness, Smirnoff vodka and Johnnie Walker whiskey.

Recently the company acquired around 50% of United Spirits, India’s largest spirit company. India’s whiskey consumption doubled during the period 2005 to 2010 and for Diageo, this market has remained largely out of reach.

Strict import laws and tariffs have prevent from Diego from entering the world’s largest whiskey market but control of United Spirits should change that.

Over the long term, Diageo is sure to profit from its Indian expansion.

Emerging marketsUnilever

My final Nisa growth pick is another play on India. Consumer goods giant, Unilever (LSE: ULVR) recently increased its stake in Hindustan Unilever Limited; Unilever’s Indian subsidiary. India is one of the world’s largest consumer markets, so Unilever’s presence within the region is exciting.

Further, Unilever is refocusing its global brand portfolio, selling off non-core, low-margin and low-growth food brands, diverting funds towards the company’s line of home care products. The home care side of the business is actually growing much faster than the food side.

Unilever is a solid pick for income seekers as well. The company currently supports a dividend yield of 3.4%.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

Rupert does not own any share mentioned within this article. The Motley Fool owns shares in Unilever. 

More on Investing Articles

Investing Articles

Publish Test

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut…

Read more »

Investing Articles

JP P-Press Update Test

Read more »

Investing Articles

JP Test as Author

Test content.

Read more »

Investing Articles

KM Test Post 2

Read more »

Investing Articles

JP Test PP Status

Test content. Test headline

Read more »

Investing Articles

KM Test Post

This is my content.

Read more »

Investing Articles

JP Tag Test

Read more »

Investing Articles

Testing testing one two three

Sample paragraph here, testing, test duplicate

Read more »